BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis

被引:18
作者
Miura, Itaru [1 ,2 ]
Zhang, Jian-Ping [1 ,3 ,4 ]
Nitta, Masahiro [1 ,5 ]
Lencz, Todd [1 ,3 ,4 ,6 ]
Kane, John M. [1 ,3 ,4 ,6 ]
Malhotra, Anil K. [1 ,3 ,4 ,6 ]
Yabe, Hirooki [2 ]
Correll, Christoph U. [1 ,3 ,4 ,6 ]
机构
[1] Zucker Hillside Hosp, North Shore Long Isl Jewish Hlth Syst, Glen Oaks, NY 11004 USA
[2] Fukushima Med Univ, Sch Med, Dept Neuropsychiat, Fukushima, Japan
[3] Hofstra North Shore LIJ Sch Med, Hempstead, NY USA
[4] Feinstein Inst Med Res, Manhasset, NY USA
[5] Dainippon Sumitomo Pharma Co Ltd, Tokyo, Japan
[6] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
Tardive dyskinesia; AIMS; BDNF; Genotype; Schizophrenia; Race; NEUROTROPHIC FACTOR LEVELS; SCHIZOPHRENIC-PATIENTS; GENETIC ASSOCIATION; CHINESE POPULATION; OXIDATIVE STRESS; NO ASSOCIATION; RECEPTOR GENE; MNSOD GENES; RISK; DRD2;
D O I
10.1016/j.schres.2013.12.011
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Tardive dyskinesia (TD) is a serious long-term consequence of antipsychotic treatment. Since brain-derived neurotrophic factor (BDNF) has potent neurotrophic activity, genetic alterations in the BDNF gene may affect antipsychotic-induced TD. Methods: Searching PubMed and Web of Science until 05/31/13, we conducted a systematic review and a meta-analysis of the effects of BDNF Val66Met polymorphism on antipsychotic-induced TD. Pooled odds ratio was calculated to assess the effects of BDNF Val66Met polymorphism on TD occurrence. Additionally, pooled standardized mean differences (Hedges'g) were calculated to assess the effects on Abnormal Involuntary Movement Scale (AIMS) total score. Results: Out of 699 potentially eligible hits, 6 studies (N = 1740, mean age = 46.0 +/- 10.4 years; males = 73.1%; Asians = 80.5%, Caucasians = 19.5%; schizophrenia = 96.2%) were included in this meta-analysis. Pooling data from all studies, no significant associations were found between BDNF Val66Met polymorphism and TD (p = 0.82) or AIMS total scores (p = 0.11). However, in studies including only Caucasians (n = 339), Met allele carriers had significantly higher AIMS total scores (Hedges' g = 0.253, 95% confidence interval = 0.030 to 0.476, p = 0.026) and non-significantly higher TD occurrence (p = 0.127). Conversely, there was no association between BDNF and AIMS scores (p = 0.57) or TD (p = 0.65) in Asians. Conclusion: Although there was no significant association between BDNF Val66Met polymorphism and TD or AIMS scores across all patients, our results suggest that BDNF Val66Met polymorphism affects severity and, possibly, TD development in Caucasians. Since the number of studies and patients was still small, additional data are needed to confirm genotype-racial interactions. Furthermore, BDNF enhancing treatments for TD may require further study, especially in Caucasians. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:365 / 372
页数:8
相关论文
共 56 条
  • [1] Relapse Duration, Treatment Intensity, and Brain Tissue Loss in Schizophrenia: A Prospective Longitudinal MRI Study (vol 170, pg 609, 2013)
    Andreasen, Nancy C.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2013, 170 (06) : 689 - 689
  • [2] Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats - Implications for tardive dyskinesia?
    Andreassen, OA
    Jorgensen, HA
    [J]. PROGRESS IN NEUROBIOLOGY, 2000, 61 (05) : 525 - 541
  • [3] BDNF in schizophrenia, depression and corresponding animal models
    Angelucci, F
    Brenè, S
    Mathé, AA
    [J]. MOLECULAR PSYCHIATRY, 2005, 10 (04) : 345 - 352
  • [4] [Anonymous], COMPREHENSIVE METAAN
  • [5] Tardive Dyskinesia and the 3-Year Course of Schizophrenia: Results From a Large, Prospective, Naturalistic Study
    Ascher-Svanum, Haya
    Zhu, Baojin
    Faries, Douglas
    Peng, Xiaomei
    Kinon, Bruce J.
    Tohen, Mauricio
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (10) : 1580 - 1588
  • [6] Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes:: a meta-analysis of pharmacogenetic interactions
    Bakker, P. R.
    van Harten, P. N.
    van Os, J.
    [J]. MOLECULAR PSYCHIATRY, 2008, 13 (05) : 544 - 556
  • [7] Candidate Gene-Based Association Study of Antipsychotic-Induced Movement Disorders in Long-Stay Psychiatric Patients: A Prospective Study
    Bakker, P. Roberto
    Bakker, Egbert
    Amin, Najaf
    van Duijn, Cornelia M.
    van Os, Jim
    van Harten, Peter N.
    [J]. PLOS ONE, 2012, 7 (05): : e36561
  • [8] Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta analysis
    Bakker, PR
    van Harten, PN
    van Os, J
    [J]. SCHIZOPHRENIA RESEARCH, 2006, 83 (2-3) : 185 - 192
  • [9] Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia
    Browne, S
    Roe, M
    Lane, A
    Gervin, M
    Morris, M
    Kinsella, A
    Larkin, C
    OCallaghan, E
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1996, 94 (02) : 118 - 124
  • [10] Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence
    Cho, Chul-Hyun
    Lee, Heon-Jeong
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2013, 46 : 207 - 213